Sign inJoin waitlistJoin the waitlist

TT

Tanya Trippett

Associate Attending Pediatrician · New York Presbyterian Hospital

Credentials: · ·

History

New York Presbyterian Hospital
Present

Memorial Sloan Kettering Cancer Center
1988–1989
Pediatrics
Duke University Hospital
1985–1988
Duke University School of Medicine
1981–1985

Research

Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers
Cell · 2020 · 1,025 citations
Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
Journal of Clinical Oncology · 2016 · 488 citations
A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic…
Blood · 2001 · 332 citations

JB
Jessica Boklan
13 papers
Lia Gore
12 papers
PS
Peter Steinherz
12 papers
JB
Joseph Bertino
10 papers
NS
Neerav Shukla
9 papers · 1 as a fellow
AS
Amy Smith
7 papers
CF
Christopher Forlenza
6 papers
Craig Moskowitz
6 papers
Cynthia Herzog
6 papers
Margaret Macy
6 papers
David Lyden
5 papers
Ira Dunkel
5 papers

Grants

Novel Antifolates in Acute Leukemia and Osteosarcoma
National Cancer Institute · K23
Contact PI · $368.5K · Sloan-Kettering Inst Can Research
1999–2002

Clinical trials

Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment
Principal investigator · Active not recruiting · Phase 1, Phase 2
Memorial Sloan Kettering Cancer Center
2016–2026
Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma
Principal investigator · Completed · Phase 2
Memorial Sloan Kettering Cancer Center
2011–2018
Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors
Principal investigator · Completed · Phase 1, Phase 2
Memorial Sloan Kettering Cancer Center
2011–2020
Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma
Principal investigator · Completed · Phase 2
Memorial Sloan Kettering Cancer Center
2007–2022